Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HALO 
Halozyme Therapeutics Inc (HALO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HALO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $70
1 Year Target Price $70
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.17% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.67B USD | Price to earnings Ratio 15 | 1Y Target Price 70 |
Price to earnings Ratio 15 | 1Y Target Price 70 | ||
Volume (30-day avg) 8 | Beta 1.17 | 52 Weeks Range 42.01 - 70.51 | Updated Date 08/15/2025 |
52 Weeks Range 42.01 - 70.51 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 1.24 | Actual 1.54 |
Profitability
Profit Margin 47.28% | Operating Margin (TTM) 62.15% |
Management Effectiveness
Return on Assets (TTM) 21.21% | Return on Equity (TTM) 179.14% |
Valuation
Trailing PE 15 | Forward PE 12.5 | Enterprise Value 8578918580 | Price to Sales(TTM) 6.5 |
Enterprise Value 8578918580 | Price to Sales(TTM) 6.5 | ||
Enterprise Value to Revenue 7.28 | Enterprise Value to EBITDA 10.83 | Shares Outstanding 116966000 | Shares Floating 115574105 |
Shares Outstanding 116966000 | Shares Floating 115574105 | ||
Percent Insiders 1.17 | Percent Institutions 98.65 |
Upturn AI SWOT
Halozyme Therapeutics Inc
Company Overview
History and Background
Halozyme Therapeutics Inc. was founded in 1998. Initially focused on oncology, it evolved into a biopharma company primarily known for its ENHANZE drug delivery technology.
Core Business Areas
- ENHANZE Technology: Halozyme's primary business revolves around its ENHANZE drug delivery platform, which allows for subcutaneous delivery of injectable biologics instead of intravenous administration. This enhances patient convenience and reduces healthcare costs.
- Royalty Revenue: Halozyme generates revenue through royalties from its partners who use ENHANZE in their commercialized products. These partnerships drive a significant portion of its income.
- Research and Development: Halozyme continues to invest in R&D to expand the applications of its ENHANZE platform and develop new technologies.
Leadership and Structure
Halozyme is led by Helen Torley (CEO). The organizational structure includes departments for R&D, commercial operations, finance, and legal, reflecting its biopharmaceutical business model.
Top Products and Market Share
Key Offerings
- ENHANZE Technology: ENHANZE enables partners to develop subcutaneous formulations of their biologics. Market share is not directly applicable, as ENHANZE is a technology platform. Partners include Roche, Takeda, and Bristol Myers Squibb. Competitors include companies with alternative drug delivery technologies, such as microsphere-based delivery systems.
- PegPH20 (discontinued): Previously, Halozyme marketed PegPH20 for certain cancer treatments, but its development was discontinued. It no longer contributes to revenue. There are many other cancer therapies, including immunotherapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by innovation, high regulatory hurdles, and strong competition. Drug delivery technologies like ENHANZE are increasingly important for improving patient outcomes and reducing healthcare costs.
Positioning
Halozyme is a key player in the drug delivery technology space, particularly for biologics. Its competitive advantage lies in the established validation and broad applicability of the ENHANZE platform.
Total Addressable Market (TAM)
The TAM for subcutaneous drug delivery of biologics is estimated to be billions of dollars, growing as more biologics seek improved delivery methods. Halozyme's ENHANZE has positioned itself to capture a substantial portion of this market via partnerships and royalty agreements.
Upturn SWOT Analysis
Strengths
- Proven ENHANZE technology platform
- Strong partnerships with major pharmaceutical companies
- Recurring royalty revenue stream
- Experienced management team
Weaknesses
- Reliance on partners' success for royalty revenue
- Dependence on a single core technology platform
- Susceptibility to patent expirations
- Past failure with PegPH20
Opportunities
- Expanding ENHANZE to new therapeutic areas
- Developing new drug delivery technologies
- Acquiring complementary technologies or companies
- Penetrating emerging markets
Threats
- Competition from alternative drug delivery technologies
- Failure of partners' ENHANZE-enabled products
- Changes in regulatory landscape
- Economic downturn impacting pharmaceutical spending
Competitors and Market Share
Key Competitors
- ARGX
- JNJ
- MRK
Competitive Landscape
Halozyme's advantage lies in its proven ENHANZE technology and established partnerships. Competitors may offer alternative drug delivery systems or focus on specific therapeutic areas. Halozyme's strong revenue from ENHANZE is a major advantage.
Major Acquisitions
Antares Pharma
- Year: 2022
- Acquisition Price (USD millions): 960
- Strategic Rationale: The acquisition of Antares Pharma expands Halozyme's product portfolio and revenue stream, adding commercial-stage products and drug-device combination capabilities.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by the success of partnered products using ENHANZE and their adoption. Historical revenue growth is important to analyse.
Future Projections: Analysts project future growth based on continued ENHANZE adoption and new partnership agreements. (Refer to analyst reports for specific numbers.)
Recent Initiatives: Recent initiatives include securing new partnerships, expanding ENHANZE into new therapeutic areas, and optimizing operations to improve profitability. Analyse recent initiatives via company announcements.
Summary
Halozyme Therapeutics is a reasonably strong biopharma company. Its ENHANZE technology and partnerships are a core strength, driving revenue. The company needs to focus on expanding its technology and portfolio, as well as mitigates reliance on partners' successes to secure future growth. While the discontinuation of PegPH20 was a setback, the acquisition of Antares Pharma diversifies the business.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Halozyme Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. It is recommended to consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Halozyme Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-03-16 | President, CEO & Director Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 350 | Website https://halozyme.com |
Full time employees 350 | Website https://halozyme.com | ||
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.